| Efficacy of the nanoparticle–drug conjugate CRLX101 in combination with bevacizumab in metastatic renal cell carcinoma: results of an investigator-initiated phase I–IIa … SM Keefe, J Hoffman-Censits, RB Cohen, R Mamtani, D Heitjan, S Eliasof, ... Annals of Oncology 27 (8), 1579-1585, 2016 | 48 | 2016 |
| Polymeric nanoparticles and cancer: Lessons learnt from CRLX101 I Gritli, E Garmey, S Eliasof, A Tellez, ME Davis, Y Yun | 8 | 2016 |
| Abstract CT090: Phase II trial of the NDC CRLX101 in combination with bevacizumab in patients with platinum-resistant ovarian cancer (PROC) C Krasner, M Birrer, C Peters, L Jayaraman, S Eliasof, A Tellez, ... Cancer Research 76 (14_Supplement), CT090-CT090, 2016 | 4 | 2016 |
| Treatment of cancer P Friedman, S Eliasof, A Senderowicz, A Tellez, D Lazarus, L Jayaraman US Patent App. 16/465,549, 2020 | 1 | 2020 |
| CRLX101, an investigational camptothecin-containing nanoparticle-drug conjugate, combined with DDR agents provides a novel approach to increasing therapeutic index LO O'Connor, AT Wang, D Jones, R Odedra, M Spreadborough, J Wilson, ... MOLECULAR CANCER RESEARCH 15, 2017 | | 2017 |
| Abstract B32: CRLX101, an investigational camptothecin-containing nanoparticle-drug conjugate, combined with DDR agents provides a novel approach to increasing therapeutic index LO O'Connor, AT Wang, D Jones, R Odedra, M Spreadborough, J Wilson, ... Molecular Cancer Research 15 (4_Supplement), B32-B32, 2017 | | 2017 |
| A camptothecin-containing nanoparticle-drug conjugate combination with DDR agents provides a novel approach to increasing therapeutic index L Oplustil O’Connor, AT Wang, DR Jones, R Odedra, M Spreadborough, ... Cancer Research 76 (14_Supplement), 3721-3721, 2016 | | 2016 |
| HIF inhibition in metastatic renal cell carcinoma (RCC): FINAL results from a phase 1-2a clinical trial evaluating the nanoparticle-drug conjugate, CRLX101, in combination with … SM Keefe, J Hoffman-Censits, RB Cohen, S Eliasof, EG Garmey, ... BJU INTERNATIONAL 116, 10-11, 2015 | | 2015 |
